This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.
Iron repletion runs in two phases at different speeds. Haemoglobin recovers in weeks; ferritin in months. Per BSG 2021: oral iron raises haemoglobin within 1-2 weeks and normalises Hb within 6-8 weeks. Continue 3 months past Hb normalisation to replenish stores. Endpoint is clinical (symptom resolution, restored stores), not a numerical ferritin target. Standard retest schedule: FBC at 2-4 weeks, FBC plus ferritin at 8-12 weeks, final ferritin at 6 months.
Enter what you have. Your ferritin alone works; the other fields sharpen the reading. Nothing you enter leaves this device. Nothing is saved. No AI is used, only published UK guideline thresholds.
This tool gives educational interpretation of published evidence. It is not personal dosing advice and it does not diagnose. It knows nothing about your history, symptoms or other results. Interpreting your results over time, alongside everything else about you, is what Nutri365 does.
Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639) demonstrated that consecutive-day dosing of 60 mg elemental iron triggered hepcidin elevations reducing absorption from the next dose by 35-45%. Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957), Stoffel 2020 (Haematologica 105(5):1232-1239) confirmed the practical implication: alternate-day dosing achieves higher cumulative fractional absorption and comparable haemoglobin response with fewer GI side effects than consecutive-day dosing.
Form choice does not materially change the repletion timeline. BSG 2021 considers ferrous sulphate, fumarate, and gluconate equivalent first-line options for repletion. Iron bisglycinate has tolerability advantages but no proven superiority on absorption rate or repletion speed. Switching between traditional iron salts is not evidence-supported.
Ferritin trails haemoglobin substantially. After Hb normalises, ferritin continues to rise over a further 3-6 months on continued repletion. BSG 2021 recommends continuing oral iron for 3 months past Hb normalisation rather than stopping at the first normal Hb. Standard retest schedule: FBC at 2-4 weeks; FBC plus ferritin at 8-12 weeks; final ferritin at around 6 months. For IDWA: no Hb endpoint, so retest ferritin and FBC at 8-12 weeks.
Documented causes of slower-than-expected response: ongoing blood loss (heavy menstrual or occult gastrointestinal); malabsorption (coeliac disease, IBD, atrophic gastritis, H. pylori, post-bariatric); inflammation suppressing absorption and elevating ferritin (Ganz 2019 NEJM 381(12):1148-1157, PMID 31532961); consecutive-day dosing hitting hepcidin rebound (Moretti 2015); co-administration with calcium, polyphenols, or antacids; thyroid medication interaction requiring spacing; inadequate dose or non-adherence driven by GI side effects (Tolkien 2015 PLoS One 10(2):e0117383, PMID 25700159).
In IDWA, retest ferritin and FBC at 8-12 weeks; if response is inadequate, reassess underlying cause rather than escalating dose blindly. Repletion duration in IDWA is more individualised than in IDA because no Hb endpoint forces the question; typically 3-6 months with ferritin retest before stopping. Pregnancy: iron requirements rise substantially; routine antenatal screening covers iron, B12, and folate. Inflammatory contexts: paired ferritin and CRP avoids misreading falsely elevated ferritin as repletion.
Concurrent intake of these inhibitors with iron can blunt absorption and slow repletion. Practical mitigation: take iron away from these (1-2 hours before or after coffee, tea, or calcium-containing foods; at least 4 hours from levothyroxine). Stoffel/Moretti programme findings on alternate-day dosing apply regardless of these timing arrangements.
| Interaction | Issue | Guidance | Citation |
|---|---|---|---|
| Iron and calcium | Calcium reduces non-haem iron absorption | Separate iron supplements from calcium-containing meals by around 2 hours | NIH ODS — Iron Fact Sheet for Health Professionals |
| Iron and tea polyphenols | Polyphenols in tea reduce non-haem iron absorption | Separate iron supplements from tea by 1-2 hours | NIH ODS — Iron Fact Sheet for Health Professionals |
| Iron and coffee polyphenols | Polyphenols in coffee reduce non-haem iron absorption | Separate iron supplements from coffee by 1-2 hours | NIH ODS — Iron Fact Sheet for Health Professionals |
Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639), Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957), Stoffel 2020 (Haematologica 105(5):1232-1239) underpin the alternate-day dosing approach. Tolkien 2015 (PLoS One 10(2):e0117383, PMID 25700159) quantifies GI tolerability of ferrous sulphate. Ganz 2019 (NEJM 381(12):1148-1157, PMID 31532961) covers anaemia of inflammation.
After 8-12 weeks of adequate adherence without expected response, BSG 2021 supports investigating underlying cause before concluding non-response: occult GI bleeding workup, coeliac serology, H. pylori testing, inflammatory markers, and review of co-administration patterns. Where investigation is complete and oral iron has genuinely failed or is not tolerated, parenteral iron (e.g. ferric carboxymaltose) is the BSG-supported next-line option. Krayenbuehl 2011 (Blood 118(12):3222-3227, PMID 21705493) anchors the IV iron measurement window at 6 weeks post-infusion. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.
Claim: doubling the dose halves the timeline. The Tolkien 2015 meta-regression found no significant relationship between iron dose and GI side-effect rate. Higher single doses do not proportionally increase absorption because hepcidin elevation after each dose dampens subsequent uptake. The Moretti 2015 / Stoffel 2017 / Stoffel 2020 findings on alternate-day dosing are the practical answer to absorption efficiency, not dose escalation. Form switching between traditional iron salts is not evidence-supported.
This entry is relevant for the following groups, conditions, and medication contexts:
Reviewed and corrected against sources on , ,